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Abstract A new concept for protein recognition and
binding is highlighted. The conjugation of small organic
molecules or short peptides to polypeptides from a designed
set provides binder molecules that bind proteins with high
affinities, and with selectivities that are equal to those of
antibodies. The small organic molecules or peptides need to
bind the protein targets but only with modest affinities and
selectivities, because conjugation to the polypeptides results
in molecules with dramatically improved binder perfor-
mance. The polypeptides are selected from a set of only
sixteen sequences designed to bind, in principle, any
protein. The small number of polypeptides used to prepare
high-affinity binders contrasts sharply with the huge
libraries used in binder technologies based on selection or
immunization. Also, unlike antibodies and engineered
proteins, the polypeptides have unordered three-dimensional
structures and adapt to the proteins to which they bind.
Binder molecules for the C-reactive protein, human
carbonic anhydrase II, acetylcholine esterase, thymidine
kinase 1, phosphorylated proteins, the D-dimer, and a
number of antibodies are used as examples to demon-
strate that affinities are achieved that are higher than those of
the small molecules or peptides by as much as four orders of
magnitude.Evaluationbypull-downexperimentsandELISA-
based tests in human serum show selectivities to be equal to
those of antibodies. Small organic molecules and peptides are
readily available from pools of endogenous ligands, enzyme
substrates, inhibitors or products, from screened small
molecule libraries, from phage display, and from mRNA
display. The technology is an alternative to established binder
concepts for applications in drug development, diagnostics,
medical imaging, and protein separation.
Keywords Binder technology.Protein.Molecular
recognition.Polypeptide.Affinity.Specificity.Diagnostics
Introduction
The recognition and binding of proteins is the most critical
molecular event in drug action, in diagnostics in vitro and in
vivo, in industrial purification of therapeutic proteins, and in
innumerable bioanalytical research applications in biotech-
nology and biomedicine. High affinity and specificity ensures
good efficacy and minimal side effects of pharmaceuticals,
and reliable identification and quantification of expression
levels of biomarkers in diagnostic applications. Understand-
ing systems biology and the search for new biomarkers in
proteomics depend on multiplexed detection formats in which
large numbers of proteins are captured on chip by the
corresponding numbers of specific high-affinity recognition
elements. The applications for molecules that bind proteins
keep expanding, and issues of affinity, specificity, robustness,
and time for development are in focus. New binder concepts
are of greater interest than ever in drug development, in
in vitro diagnostics, and in medical imaging.
Current binder technologies can, somewhat surprisingly,
be grouped into two categories. They are either biological
in origin or are small organic molecules prepared by
synthesis. Antibodies remain the golden standard of
diagnostics [1] and have in recent years become the most
important new class of pharmaceutical molecules [2]. Well
established procedures for development, production, and
use remain strong points of antibody technologies in life
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forms the basis for therapeutic applications by reducing
immunogenicity. Insufficient specificity (cross-reactivity),
interference phenomena and poor robustness remain weak
points. New developments include single-chain antibodies
[4] that are smaller and, in general, more robust than
monoclonal antibodies. To partially overcome the weak-
nesses of the antibody technology phage display techniques
have been employed in the engineering of proteins for
binder applications. Examples include DARPins or ankyrin
repeats [5], affibody molecules derived from protein A [6],
and lipocalins [7]. These binders are all prepared by protein
expression and identified by selection rather than design,
they are robust and capable of high affinities and
selectivities. The building blocks are the common amino
acids. Nucleic acids are also used in protein recognition.
Aptamers are polynucleic acids selected from large pools of
binder candidates [8]. A frequently used argument in favour
of selection methods is that huge libraries of candidates can
be searched efficiently and that this feature makes it more
likely to find good binders. In these technologies a single
unique sequence with a well-defined fold is required to
recognize a target protein.
Small organic molecules prepared by organic synthesis
still form the bulk of pharmaceuticals in the clinic. Their
molecular weights are low in comparison with proteins, the
well-known Lipinski’s rule of five state that the molecular
weight of an organic molecule should be 500 D or less in
combination with a high level of lipophilicity (logP=5) to
show acceptable bioavailability [9]. Organic synthesis
minimizes batch to batch variations and eliminates risk of
contamination from biological sources but the efforts
needed to reach affinities and selectivities required for the
recognition and binding of proteins in biological samples or
in vivo are considerable. The costs involved in the develop-
ment of small organic high-affinity molecules for efficient
protein recognition can only be justified in pharmaceutical
applications, and small organic molecules have had little
impact in the field of diagnostics. In pharmaceutical applica-
tions the penalties are severe, because 93–97% of all drug
projects are cancelled never to reach the clinic, often at a late
stage of development. The reasons are most often unexpected
toxicity or poor efficacy.
The growing need for specific high-affinity protein
binders in life science drives the search for new molecular
concepts and technologies. The search is beginning to
expand beyond small organic molecules and monoclonal
antibodies to include also macrocycles and peptides [10,
11]. Peptide–protein interactions are common in the control
and modulation of cellular function, intercellular commu-
nication, immune responses, and signal transduction. The
design of agonists and antagonists based, for example, on
the introduction of conformational constraints, and back-
bone and side-chain modifications in peptides, is today an
established drug-development strategy.
This review covers a new synthetic strategy for
molecular recognition of proteins based on the conjugation
of small organic molecules or peptides to designed
polypeptides [12, 13]. The main strengths of the concept
are that a small set of polypeptides can be used to develop
binder molecules for any protein by conjugation to small
molecules or peptides with only modest binding capacities,
and that the binder molecules target the proteins that the
small molecules recognise but with much improved affinity
and selectivity. The review does not cover small molecules
conjugated to polypeptides specifically prepared to recog-
nize a given protein, because this approach is best described
as a form of fragment-based design, and is less general. The
binder technology combines the properties of biomolecules
with those of small organic molecules. In the following
text, in the interest of clarity, the term “binder molecule”
exclusively refers to a designed polypeptide conjugated to a
small organic molecule or short peptide, typically via a
spacer. A “ligand” is a small organic molecule or peptide
that binds to a protein and used to form binder molecules,
whereas a “binder” is any molecule that binds to a protein.
The polypeptide conjugate binder concept
According to this concept a fully assembled binder
molecule consists of a small organic molecule or peptide
that is linked with or without an interconnecting spacer to a
42-residue polypeptide selected from a set of only sixteen
sequences (Fig. 1)[ 12]. The small molecule must bind to
the protein but only modest affinity is required. Conjuga-
tion to the polypeptide provides an assembled binder
molecule that binds the protein with an affinity that is as
much as four orders of magnitude higher than that of the
small molecule and with increased selectivity [14]. The
small organic molecule or peptide used as ligand, binds to
its binding site, and the attached polypeptide finds and
occupies the most favourable site of interaction on the
protein surface in close proximity to the binding site of the
small molecule [15]. In contrast with antibodies it is not
preorganized to recognize a specific epitope but adapts and
binds to the protein surface within the area that can be
reached by the spacer. The polypeptide is unordered and
proteins are often plastic with amino acid residues that flip
and change conformation in the bound state. The bound
conformation can therefore not at this stage be predicted
with any accuracy from modelling. Therefore the technol-
ogy is designed to enable rapid assembly and screening and
the time for binder development is, by comparison, short.
The key to the binder concept is the design and function
of the polypeptides that form the universal set of sixteen
1654 L. Baltzersequences, a number that is very small in comparison to the
large libraries used in binder development based on
immunization or selection (Fig. 2). The main reason that
only sixteen sequences are needed to develop binders for, in
principle, hundreds of thousands of proteins is that the
contribution of the polypeptide to the overall binding is
relatively small. By design, the polypeptides are given the
capacity to present many potentially interacting groups to
the target protein surface and it is only necessary for a few
of those to engage in productive binding to raise the affinity
1000-fold, for example. In order for the assembled binder
molecule to have a dissociation constant that is three orders
of magnitude lower than that of the small molecule ligand,
the polypeptide needs to contribute less than 20 kJ mol
−1 of
binding energy at room temperature [16]. That amount of
binding energy corresponds to a few hydrophobic contacts
between 2 or 3 leucine residue side chains from the
polypeptide and hydrophobic groups presented by the
protein, or a few hydrophobic contacts in combination with
charge–charge interactions and hydrogen bonding. The
polypeptides were given some propensity for forming
amphiphilic helices with two helices linked by a short loop
[17, 18] and the design is based on two structural variables.
There are four different combinations of charged residues
and four different positions of attachment of the small
molecule ligand, altogether sixteen combinations and thus
sixteen sequences (Fig. 2)[ 12] Thehydrophobicresiduesare
the same throughout the set and the charged residues are
introducedalongtheperimeterofthehydrophobicfacesofthe
amphiphilic helices to bring them into close proximity to
protein surface residues. Although the polypeptide itself is a
weak binder, it is covalently linked to the small molecule
which binds tothe protein,and the entropicpenalty associated
with the polypeptide–protein interaction has therefore been
eliminated or, at least, drastically reduced [16]. Because only
a few interactions are required between polypeptide and
protein, only a few amino acid residues have to be involved
in binding to a given protein, and a polypeptide of 42 amino
acid residues represents a large number of combinations of
amino acid side chains capable of providing the necessary
binding energy. The capacity to bind to a variety of potential
binding sites on the surfaces of many proteins is thus
embedded in the polypeptide construct.
The polypeptides were designed to supplement the
binding energy provided by the small molecule ligand
predominantly by hydrophobic interactions. Charged resi-
dues were introduced in positions next to the hydrophobic
ones to increase selectivity due to charge–charge interac-
Fig. 1 Binder molecule concept
illustrated for human carbonic
anhydrase II (HCAII). Benzene-
sulfonamide is a small molecule
inhibitor known to bind HCAII
with a Kd of 1.5 μmol L
−1.
Numerous crystal structures are
available to show that the sul-
fonamide group coordinates to
the active site Zn
2+ ion at the
bottom of a 10Å deep pocket.
From the available structural
information it was assumed that
an aminohexanoic acid spacer
would provide sufficient dis-
tance from the active site to the
protein surface to enable the
polypeptide to fold and bind
cooperatively with the benzene-
sulfonamide group. The amino-
hexanoic acid spacer was
incorporated by organic synthe-
sis and the active ester was
reacted with each member of the
set of polypeptides to form the
candidate binder molecules.
Evaluation by fluorescence titra-
tion, indicated by the coumarin
fluorophore, identified high-
affinity binders. PDB ID: 1CA2
Crossing borders to bind proteins 1655tions between residues in the polypeptides and those on the
protein surface. A helical conformation was expected to
improve the presentation of the hydrophobic residues and in
the helical conformation the charged amino acid residues
introduced next to the hydrophobic ones are forced in
contact with the residues on the protein surface to enhance
selectivity (Fig. 3). In solution the polypeptides form helix–
loop–helix motifs that dimerise to form four helix bundles
at micromolar concentrations but dissociate to unordered
monomers at nanomolar concentrations [12, 17]. Their
NMR spectra show the hallmarks of molten globules and
they melt uncooperatively. The concept is more closely
related to so called intrinsically disordered proteins [19],
proteins that fold productively only in contact with their
targets, than to antibodies or engineered proteins. As a
consequence of the small size the binders do not denature,
and they can be stored in the lyophilized state without loss
of activity. They are extremely robust and suitable for
Fig. 2 The set of sixteen poly-
peptide sequences used to de-
velop binder molecules by
conjugation to small organic
molecules or peptides. Aspartic
and glutamic acids are colour-
coded red, whereas arginines are
blue, to illustrate the systematic
variation of charged residues.
The sites of incorporation of
fluorophores and small molecule
ligands are shown in bold italics
and underscored and are evident
from the sequence name.
1-C15L8 has a coumarin fluo-
rophore at the side chain of
Lys15 and a small molecule
ligand at the side chain of Lys8,
etc. All amino terminals are
acetylated whereas carboxy
terminals are amidated in some
sequences and free in others
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Fig. 3 Schematic illustration of principle behind design of helical
propensity in polypeptide sequences. The amphiphilic helices have
hydrophobic residues in positions that are flanked by charged
residues. Hydrophobic residues in the polypeptide sequences are
expected to interact with hydrophobic residues exposed on the protein
surface. In a helical conformation the charged flanking residues are
forced in contact with residues on the protein surface. If charged
residues are forced in contact with residues of the opposite charge the
polypeptide will bind, left panel. If not, binding will be very weak or
undetectable, right panel
1656 L. Baltzerapplications in which optimum storage conditions are not
available or not convenient. There is, as yet, no high-
resolution information about the structure of the binder
molecules complexed to proteins and understanding of how
they actually bind remains hypothetical. Only indirect
evidence from NMR and CD spectroscopy exists in support
of the expectation that the polypeptides form helices and
fold into hairpin motifs in the bound state [15].
The small molecules or peptides are conveniently obtained
from the pool of known endogenous ligands described in the
literature. A selective high-affinity binder for the C-reactive
protein (CRP) was developed from phosphocholine that is
known to bind CRP with a Kd of 5 μmol L
−1 in the presence
of Ca
2+ [12] and a binder for thymidine kinase 1 (TK1) was
developed from deoxythymidine (Stauffiger, A., Sun, X.,
Virtanen, A., Baltzer, L., unpublished), a substrate for the
kinase with similar affinity. The small molecule can also be
identified from a search of the organic chemistry literature.
Proteins that have reached the status of biomarkers have
frequently been well investigated and the literature is rich in
small organic molecules designed to bind important bio-
markers, but with affinities and selectivities insufficient for
biomedical applications. They are excellent starting points
for the development of binder molecules. When small
molecule ligands for proteins are not available they can be
identified from selected libraries by spectroscopic methods.
There are today well established NMR spectroscopy experi-
ments designed for this particular purpose based on the
effects that binding of small molecules have on chemical
shifts or relaxation [20, 21]. The search for small molecules
that bind poorly characterized proteins may seem like a
cumbersome and tedious approach but the identification of
moderately tight binders for proteins is far less ambitious
than the development of tight binders. Peptides that bind
proteins are identified from the peptide epitopes of native
protein ligands if the target protein is involved in protein–
protein interactions or from phage display or m-RNA display
[22, 23]. Again, the peptides that bind proteins need not bind
with high affinities, because polypeptide conjugation enhan-
ces binder performance.
A binder molecule for the D-dimer protein with a Kd of
2n m o lL
−1 was obtained by conjugating the GPRP
tetrapeptide, that binds the D-dimer with 25 μmol L
−1 affinity,
to the polypeptide scaffold 4-C15L8 (Fig. 4)[ 24]. The rate-
limiting step in the development of binder molecules based on
small organic compounds is the organic synthesis required to
modify the small molecule ligand. The introduction of a
spacer carrying functional groups for conjugation to the
polypeptide, for example p-nitrophenyl esters, will take weeks
and may even take months of organic synthesis. The conjuga-
tionofpeptidesis,bycomparison,straightforward,because of
the well advanced stage of solid-phase peptide synthesis. A
limitation of the concept is that purified target protein must be
available in the development process. Antibodies, in contrast,
may be produced from protein sequence information.
Selection of the spacer is based on available crystal
structures or trial and error. From crystal structures the
required spacer length can be estimated on the basis of the
distance from the small molecule binding site to the surface
of the protein where the polypeptide binds. In the case of a
binder molecule for human carbonic anhydrase II (HCAII),
aminohexanoic acid was selected [25, 26]. The pocket is
approximately 10Å deep and the combination of benzenesul-
fonamide carboxylic acid with the aminohexanoic acid was
expected to enable the polypeptide to dock on the surface of
the protein with thesulfonamidegroup coordinated to the Zn
2+
Fig. 4 Illustration of a binder
molecule based on a short pep-
tide fragment. GPRP binds to
the D-dimer with a Kd of
25 μmol L
−1 in a surface-
exposed position. Conjugation
to polypeptides gives a fully
assembled binder molecule that
binds with a Kd of 2 nmol L
−1.
Representation of D-dimer
structure from crystal structure.
PDB ID:1FZB
Crossing borders to bind proteins 1657ion in the active site. The size of the spacer was critically
evaluated using a set of aminocarboxylic acids with the
amino and carboxylic acid groups separated by 0 to 10
methylene groups [15]. Affinities were determined by
fluorescence titration and the spacers with zero, one, three,
and four methylene groups had approximately the same
affinity as benzenesulfonamide, with dissociation constants
between 3 and 0.8 μmol L
−1, whereas the spacer with five
methylene groups bound HCAII with a Kd of 20 nmol L
−1
[27]. The increase in spacer length by a single methylene
g r o u pw a st h u ss h o w nt ol e a dt oa na f f i n i t yi n c r e a s eb ya
factor of 40 and a further extension by two methylene groups
gave rise to a further fourfold increase in affinity. The results
showed that a spacer long enough to extend out of the pocket
provided enough conformational freedom for the polypeptide
to fold and bind to a site on the protein surface, whereas too
short a spacer prevented the polypeptide from folding and
binding in the constricted space of the binding pocket. A
binder for acetylcholine esterase with an active site buried in
a 20Å deep pocket required a 16 atom spacer for binding
(Winander, C., Tegler, L.T., Baltzer, L., unpublished). In all of
the reported binder molecules aliphatic spacers were used and
the PEG spacers commonly used in bioconjugation chemistry
were only used for the purpose of avoiding interactions with
the protein that could interfere with binding.
Polypeptide conjugate binder molecules
The most well characterized binder molecule is that which
bindsCRP[28]. CRP is a general inflammation marker and a
component of the complement activation system. CRP is up-
regulated as a consequence of, for example, viral or bacterial
infections and is measured routinely in hospitals. The so
called high-sensitive CRP test is used as a cardiovascular risk
marker [29]. The binder molecule was designed on the basis
of the crystal structure of the CRP–phosphocholine complex
[30] which suggested that one of the methyl groups of the
phosphocholine ammonium ion could be replaced by an
aliphatic spacer without loss of binding affinity. The
phosphate group binds via intercalating Ca
2+ ions to the
side chains of aspartic acids, glutamic acids, an asparagine,
and a glutamine residue. Instead of a methyl group the
phosphocholine derivative was equipped with an aliphatic
spacer carrying a terminal p-nitrophenyl ester. It was
subsequently reacted with each of the sixteen members of
the designed set of polypeptides to form the candidate binder
molecules (Fig. 5). There is only a single free lysine in each
polypeptide and the N-terminal amino groups are all
acetylated to avoid incorporation of multiple ligands.
Screening by fluorescence titration in microtitre plate format
revealed an unusually large number of tight binders, eleven
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Fig. 5 The design of the binder
molecule for the C-reactive pro-
tein (CRP) was guided by in-
spection of the crystal structure
of the CRP–phosphocholine
complex. CRP is a symmetric
pentamer and each of the sub-
units binds one phosphocholine
molecule with a Kd of
5 μmol L
−1. The phosphate
group coordinates to aspartic
and glutamic acids, and to an
asparagine and a glutamine res-
idue via a Ca
2+ ion. The trime-
thylammonium ion, in contrast,
was not involved in highly
specific interactions and one of
the methyl groups of phospho-
choline was therefore replaced
by an aliphatic spacer carrying
an active ester endgroup, to
enable conjugation to the free
lysine residue in each of the
polypeptides of the sixteen-
membered set. PDB ID:1B09
1658 L. Baltzerout of sixteen candidates responded in the presence of CaCl2
to the presence of CRP in a way that suggested their
dissociation constants were in the low nanomolar range or
lower. Evaluation by SPR biosensor analysis (Biacore) was
largely in agreement with screening by fluorescence in
solution, and showed that the effect on affinities was
essentially because of reduced kinetic off-rates although
effects on on-rates were also observed. The kinetic behaviour
could not be described by single exponential functions but
was more complex; no standard equations available from the
commercially available software showed good correlation
with the experimental data, mainly because binding did not
show saturation. This issue remains unresolved as solution
titrations saturate at concentrations where saturation is not
observed by SPR analysis. Lack of saturation is observed
also with other protein–binder complexes but only in the
analysis by SPR. The binder molecules shown to have the
highest affinities for CRP out of the sixteen candidates were
the same, with one exception, irrespective of method, and Kd
values in the high picomolar to low nanomolar range were
clearly obtained by conjugating polypeptides to the phos-
phocholine derivative that binds CRP with a dissociation
constant of 6 μmol L
−1 [31]. The strongest binders were
found in the group with phosphocholine linked to the
polypeptides 4-C37L34, 4-C10L17, and 4-C25L22, with
that of 4-C10L17 being the binder molecule with highest
affinity in most applications. Pull-down experiments with
human serum from patient samples were used to evaluate
selectivity, and binder molecules were compared with an
avian antibody developed towards CRP. SDS-PAGE showed
that 4-C10L17 conjugated to phosphocholine via a spacer
was as selective as the antibody in human serum. Selectivity
equal to that of the antibody was also observed in a variety
of bioanalytical test formats including ELISA (see below).
The first example of a binder molecule based on a small
organic molecule with moderate affinity for a protein
conjugated to a polypeptide not specifically developed to
bind the protein was reported in 2002 [25]. A 42-residue
polypeptide, KE2, was linked via an aliphatic spacer to
benzenesulfonamide, a known inhibitor of HCAII with a
dissociation constant of 1.5 μmol L
−1, to form a binder
molecule that bound HCAII with a dissociation constant of
5 nmol L
−1 [15]. HCAII is an enzyme that catalyzes the
interconversion of bicarbonate and carbon dioxide, and is
not a commonly used biomarker although it is a drug target
for glaucoma [32], and there are reports to suggest that it is
an emerging biomarker for cancer [33]. Recently, the
detection of HCAII was reinvestigated using the set of
sixteen designed polypeptides [14]. Again a strong binder
was identified with a Kd of 17 nmol L
−1. The selectivity
towards HCAII of the binder 4-C37L34 conjugated to
benzenesulfonamide was evaluated by pull-down experi-
ments in freshly drawn whole blood with the red blood cells
lysed by the addition of distilled water. Lysis was necessary
to access HCAII, since HCAII is not present in serum
unless the red blood cells leak due to damage inflicted on
the cell wall. Human carbonicanhydrase I (HCAI)alsoexists
in red blood cells, at a concentration 5–7-fold higher than that
of HCAII [34], but with less catalytic activity. HCAI and
HCAII are 60% homologous with nearly identical molecular
weights and cannot be separated by SDS-PAGE. Both
isoforms bind benzenesulfonamide with essentially identical
affinities; reported Kd values vary between 1.3 and
1.5 μmol L
−1 for HCAII [34–36] and between 1.1 and
3.9 μmol L
−1 for HCAI [35, 37]. The conjugation of
benzenesulfonamide to polypeptides was expected to gener-
ate binder molecules with differences in affinity as the
electrostatic profile of the protein surfaces differ, and
determination of dissociation constants by SPR analysis
revealed a difference in affinity by a factor of 30 [14].
The results suggest that binder molecules with increased
selectivity can be obtained for difficult small molecule
targets using the polypeptide conjugation technology.
These examples take advantage of an endogenous ligand
and a known enzyme inhibitor. Enzyme substrates and
products can also be used although it would be expected
that an enzyme substrate undergoes a chemical transforma-
tion and become modified whereas a product of an enzyme-
catalyzed reaction should be expelled. Thymidine kinase
catalyses the phosphorylation of deoxythymidine to form
the corresponding nucleotide, and thymidine kinase 1
(TK1) is a biomarker for cancer [38]. Conjugation of
deoxythymidine to the polypeptides gave rise to several
binder molecules with low nanomolar affinities (Stauffiger,
A., Sun, X., Virtanen, A., Baltzer, L., unpublished). In the
presence of ATP, to mimic the detection of TK1 in serum,
the binder molecule was phosphorylated, as demonstrated
by MALDI-TOF mass spectrometry. Surprisingly both the
substrate-based and product-based binder molecules have
very high affinity for TK1, in the low nanomolar range or
better according to fluorescence titration. The reason that
phosphorylated deoxythymidine conjugated to a polypeptide
bound strongly to the enzyme is the considerable increase in
affinity of the assembled binder in comparison with the
phosphorylated substrate, the reaction product.
Peptides are excellent ligands for binder development.
The tetrapeptide GPRP has been shown to bind to the
D-dimer protein, a well known biomarker for thrombosis
[39], with 25 μmol L
−1 affinity [24]. The conjugate formed
by attaching GPRP to 4-C15L8 via a six-carbon spacer
bound the D-dimer with 3 nmol L
−1 affinity, an increase by
four orders of magnitude over that of the tetrapeptide [40].
GPRP was shown to completely inhibit binding, and that
the conjugate binds exclusively and specifically to the
GPRP binding site. The D-dimer is a degradation product
from fibrinogen and arises as a result of the formation of
Crossing borders to bind proteins 1659blood clots. It is a biomarker of great diagnostic value in
the clinic.
The recognition of antibodies is conveniently carried out
by conjugating epitopes recognized by the antibody to a
polypeptide followed by immobilization of the binder
molecule in the wells of a microtitre plate and an ELISA
using commercially available anti-antibody antibodies for
detection. Alternative methods include the direct immobiliza-
tion of the epitope or the immobilization of streptavidine
followedbycapture ofthe biotinylatedepitope.The use ofthe
synthetic peptide–polypeptide conjugate was shown to give
better reproducibility than alternative methods, probably
because of increased affinities and improved presentation of
the peptide antigen (Fromell, K and Baltzer, L. unpublished).
A consequence of the binder molecule concept is that if the
small molecule ligand recognises not a specific epitope or
binding site of a given protein but a specific group found in
proteins, for example as a result of post-translational
modification, then binders for groups of proteins can be
developed. Phosphorylation is the most commonly occurring
posttranslational modification [41] and a small molecule
binder for phosphate was linked to the polypeptides in the
search for binder molecules for groups of phosphorylated
proteins, possibly all [42]. The small molecule ligand
complexes two Zn
2+ ions and binds phosphate ions with
dissociation constants reported to be in the range from 28 to
640 μmol L
−1 [43]. The small molecule ligand was
conjugated to the side chain of a lysine residue in eight of
the polypeptides without connecting linker, because the
objective was to bind phosphoserines and phosphothreonines
that do not extend far from the protein surface (Fig. 6). The
binder molecule for phosphorylated proteins formed by
conjugationtothepolypeptide4-C15L8ofthesmallmolecule
ligand followed by Zn complexation, binds the model protein
α-casein with a Kd of 17 nmol L
−1,e x t r a c t sα-casein from a
10 nmol L
−1 solution, is not replaced by a 10,000-fold excess
of phosphate ions, and extracts α-casein specifically from
spiked human serum [42]. The same binder molecule binds
β-casein and the phosphorylated proteins Erk1 and Erk2, but
not Akt1 and ovoalbumin. The concept is being extended to
the detection of large groups of phosphorylated proteins by
combination of a number of binder molecules from the
candidate set. The binder molecule was also immobilized on
polystyrene beads and used to capture α-casein under flow
on a column (Slosarczyk, A., Baltzer, L. unpublished). The
captured α-casein was released by 0.1% formic acid and
identified in the eluate by mass spectrometry. An interesting
application is the use of columns developed for capture of
post-translational modified proteins in combination with
mass spectrometry or SDS-PAGE.
Applications
Antibodiesarethegoldenstandardofbioanalyticalassayswith
experimental procedures developed to a level where antibody-
based ELISAs and pull down experiments are used routinely
also in non-specialist laboratories. For comparison, the binder
molecules reviewed here have been included in standard
bioanalytical test formats and compared with antibodies. The
binder molecule for CRP was used as capturing agent in an
ELISA used to detect CRP from patient sera with HRP
conjugated antibodies used for detection [12]. The dose–
response curve was comparable with that obtained using a
commercially available antibody-based sandwich. The CRP
binder molecule was also used in a pull-down experiment
followed by detection with SDS-PAGE. The protein bands
extracted by the binder molecule from patient serum with up-
regulated CRP levels were essentially identical to those
extracted by an avian antibody to CRP. While antibodies are
typically immobilized simply by incubation and non-covalent
attachment to hydrophobic surfaces such as polystyrene, the
synthetic binder molecules were immobilized using Pluronics
molecules that form self-assembled PEG monolayers carrying
activated disulfide end groups and react spontaneously in an
exchange reaction to form disulfide bonds with unprotected
thiols. The Pluronics molecule has a polypropyleneoxide base
which is highly hydrophobic, and two PEG arms with
pyridylsulfide (PDS) groups coupled to the terminal thiols
[44]. CRP binder molecules equipped with unprotected Cys
residues in the loop region were linked to Pluronics
molecules immobilized on the surface of polystyrene beads
and in the wells of polystyrene microtitre plates. This setup
provided results in pull down experiments and ELISAs that
were comparable with those based on antibodies with regard
to specificity and level of non-specific binding. In contrast,
Fig. 6 Binder concept for recognition of proteins phosphorylated at
side-chains of serine and threonine residues. Small molecule binds
two Zn
2+ ions in fixed geometry that binds phosphate ions.
Phosphoserines and phosphothreonines do not extend far out from
the protein surface so no spacer was introduced
1660 L. Baltzerthe immobilization of binder molecules on a diamond surface
using the Pluronics technology provided a test format with
excellent performance and much beyond that shown by
antibodies in standard formats with regard to suppression of
non-specific binding [45]. The signal-to-noise ratio obtained
was unprecedented for low concentrations of CRP. While
diamond surfaces will remain at the research stage for some
time and is not likely to reach research laboratories soon, the
excellent performance of diamond surfaces coated with
Pluronics suggest that advances in materials science can be
used to dramatically improve current test formats.
Nitrocellulose membranes are well established and inex-
pensive bioanalytical test platforms. Immobilization of cap-
turing molecules on nitrocellulose is achieved by baking at
high temperature, typically 70 °C or above. The functional
membrane allows all biomolecules that are not specifically
recognized by the capturing element to pass through to an
adsorbent fixed under the membrane, while retaining the
target molecules for detection. Current detection methods
include the addition of binders, most often antibodies,
conjugated to gold nanoparticles followed by quantitative
measurement ofthe red colourby spectroscopic methods.The
CRP binder molecule 4-C10L17-PC6 was immobilized on
nitrocellulose by baking at 100 °C for 12 h. CRP from serum
was captured without detectable leakage demonstrating that
theperformanceofthebinderwasequaltothatoftheantibody
of the commercially available test [46].
A test format somewhat more ingenious in nature was
developed on the basis of two binder molecules, one that self-
associated in the presence of Zn
2+ ions and one that bound
HCAII [47]. The binder molecules were co-immobilized on
gold nanoparticles and in the presence of ZnCl2 the gold
nanoparticles aggregated to give an intense violet colour
because of the gold nanoparticle resonance phenomenon.
After addition of HCAII the nanoparticles were forced apart
by the bulkiness of the protein, resulting in a clearly visible
change of colour to red. This test format is useful for the
detection of proteins, but not for quantification, because the
colour transition takes place over a narrow concentration
range.
The development of chip-based technologies using non-
sandwich detection formats are of considerable interest,
becauseofthereducedcomplexityandshortenedmeasurement
time. In addition, the increased information content, including,
for example, binding kinetics, obtained from modern measure-
ment devices suggests they will be the standard platforms in
point of care applications very soon. Optical chip-based
technologies based on change in refractive index and layer
thickness provide better results the smaller the recognition
element. Reflectometric interference spectroscopy (RifS) [48]
is an optical detection method based on interference between
light beams reflected at the interfaces of a slide coated with
recognition elements as a function of binding. The technology
is robust and does not depend on sophisticated chip
technology for analysis—simple glass slides are sufficient.
Two CRP binder molecules were covalently immobilized on
glass chips and evaluated by RifS for the purpose of detecting
CRP in human serum. The binder technology is an excellent
alternative to antibodies in chip-based detection formats as it
provides an opportunity to implement large ranges of
detection because of to the wide range of affinities that is
obtained in the screening procedure [49].
Polypeptide conjugate binder technology thus shows great
promise as provider of recognition elements to be applied in
modern bioanalytical measurement formats. The binder
molecules are robust and prepared by synthesis, they are easy
tomodifysite-specifically,anda range ofaffinitiesisobtained
as a consequence of the variation in affinity enhancement
provided by the polypeptides. The incorporation offunctional
groups for immobilization or for linkage to fluorophores,
nanoparticles, radiolabels, etc., is well controlled.
Binder molecule development
An important aspect of any binder technology is the effort
required to develop binders for specific proteins, equipped
for given applications, and what skills are required. The
rate-limiting step in the preparation of synthetic binder
molecules is the synthesis of the small molecule ligand or
peptide equipped with spacers and functional groups for
polypeptide conjugation, e.g. spacers with p-nitrophenyl
ester end groups. The synthesis of the p-nitrophenyl ester of
phosphocholine required seven steps of intermediate diffi-
culty [12]. The synthesis of the small molecule ligand for
HCAII equipped with a spacer and an active ester was, by
comparison, simple and required only three steps, because
the carboxylic acid of benzenesulfonamide is commercially
available [25]. An extreme example was the synthesis of
the ligand for the vitamin D binding protein, which required
23 steps, and a synthesis to be attempted only by highly
experienced synthetic organic chemists [50]. Consequently,
binder molecule development depends to a large extent on
the small molecule binders that are available and known to
bind to the target. The development of binder molecules
based on small molecules depend primarily on experience
in organic synthesis whereas the development of binder
molecules based on peptides depend on peptide synthesis
and are by comparison straightforward to prepare.
The preliminary evaluation or screening of binder
performance is carried out in microtitre plate format, by
addition of solutions containing 500 nmol L
−1 binder
molecule equipped with a fluorophore, for example dansyl
or coumarin, to wells coated to avoid non-specific binding
[12]. The binder molecules are small and passivation by
BSA, the standard for antibody-based tests, is not sufficient
Crossing borders to bind proteins 1661to avoid non-specific binding. Pluronics are conveniently
used to coat surfaces but home-made “sticky” peptides may
serve as alternatives. In test formats where the binder
molecules are covalently linked to the surface and not free
in solution, special passivation is not required.
The addition of protein in 500 nmol L
−1, 1,000 nmol L
−1,
and 1,500 nmol L
−1 concentrations to wells containing
500 nmol L
−1 binder molecule followed by the measurement
of fluorescence intensity enables simple and rapid estimation
of affinity (Fig. 7). If the fluorescence is affected by the
addition of protein, binding has been established. If the
fluorescence intensity does not increase or decrease further
uponadditionofmoreprotein,thenbindinghasbeensaturated
at binder and protein concentrations of 500 nmol L
−1.
Assuming an experimental uncertainty of 10% the concen-
tration of the complex is 450 nmol L
−1 and the concentration
of the free binder and free protein is 50 nmol L
−1.F r o m
these concentrations a dissociation constant of 5 nmol L
−1
can be estimated, which is the dissociation constant of a
high-affinity binder. The estimate is, of course, approximate
but the screening procedure and the identification of high-
affinity binder molecules from the fluorescence based assay
are rapid and efficient.
Further evaluation of “hits” is carried out by SPR
biosensor analysis, by more accurate fluorescence titra-
tions, by ELISA, and by pull down experiments, with a
focus on accurate dissociation constants and selectivity in
serum or blood.
Robustness, serum, and chemical stability
Unfolding and aggregation of proteins, or denaturation,
does not in general occur with polypeptides with unordered
conformations. Unlike antibodies the binder molecules that
are 42-residue polypeptide conjugates can be heated and
cooled to room temperature without loss of function [17].
The effect of temperature on the helical signature of the
polypeptides was shown to be reversible by CD spectroscopy.
High temperature or storage at room temperature therefore
does not degrade the performance of the binder molecules.
Degradation of peptides by proteolytic enzymes is known to
occur rapidly in vivo. Human serum contains proteolytic
enzymes and incubation in serum will cause partial degrada-
tion of peptides and proteins, although folded proteins are
moreresistanttoenzymaticdegradation.Theproblemismuch
more pronounced with in vivo applications. Artificial amino
acids and side-chain modifications of common amino acids
increase lifetimes of peptides because they are not recognized
by native enzymes and, therefore, not hydrolyzed. Incorpora-
tionoforganicsubstituentsatthesidechainsoflysineresidues
was shown to increase the lifetime of the polypeptide
decorated with two substituents (Ramapanicker, R. unpub-
lished). Non-natural amino acids also protect neighbouring
amide bonds from hydrolysis and the level of protection from
proteolysis requiredcanbefurthercontrolledbyincorporation
of non-degradable amino acids, for example β-amino acids
[51]o rD-amino acids. The polypeptide 4-C15L8 was
completely degraded in less than an hour but incorporation
of a phosphocholine group in position 8 and a dansyl group
in position 5, reduced degradation in human serum at 37 °C
to approximately 20% in two hours, and further incorpora-
tion of a substituent in the loop region formed a polypeptide
conjugate for which no degradation was observed after five
hours in human serum at 37°C (Ramapanicker, R. unpub-
lished). Incorporation of organic groups at the side-chains of
amino acid residues in polypeptides therefore extends the
lifetimes in serum to levels that can be tuned by adjusting the
number of substituents or unnatural amino acids that are
incorporated.
Fig. 7 Illustration of fluorescence titration for identification of tight
binders in rapid screening procedure. Left panel shows a “hit” because
the fluorescence emission spectrum of 500 nmol L
−1 of binder
molecule (blue trace) is affected by addition of 500 nmol L
−1,
1,000 nmol L
−1 and 1,500 nmol L
−1 protein (green, red, and violet
traces), and therefore binds to the protein. Because there is no further
change in the fluorescence spectrum after addition of one equivalent
of protein, binding is saturated. The right panel shows the
corresponding fluorescence emission spectra but here the intensity
changes for each addition of protein showing that binding is not
saturated and is therefore weaker. There is no need to record the full
spectra, although they are shown here to illustrate the principle. Only
the emission at the wavelength of maximum intensity needs to be
recorded to avoid bleaching
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New binder technologies are emerging to supplement
antibodies and small organic molecules as binders for
proteins in bioanalytical and biomedicinal applications.
Most often engineered antibodies and proteins or organic
molecules with molecular weights larger than 500 D are
considered. The advantages of biomolecules in protein
recognition are the many hydrophobic groups, hydrogen
bonds, and charge–charge interactions that can be used to
form bonds to the analyte and the preorganization of
structures that reduce entropy related to binding. Also, the
access to efficient development strategies is an advantage,
although the time to robust, specific, high-affinity binders is
often long. The advantages of small organic molecules are
the preorganization of hydrogen bond donors and acceptors
that favour binding for reasons of entropy. In addition,
synthetic organic chemistry can be used for systematic
modification of structure. However, the efforts needed to
develop small molecule binders with high affinity and
specificity are substantial. Binders that take advantage of
both of these molecular aspects have great potential in binder
development. So far, only a few examples have been reported
based on the polypeptide conjugate technology, in compari-
son with the large numbers of antibodies and small organic
molecules already in use. Nevertheless, the technology
reviewed here and others are emerging toaddress the pressing
needs of the pharmaceutical and diagnostic industries as the
healthcare system remains the most important endeavour in
biotechnology. The binder molecule concept has been proven
to have great potential in that perspective. Other technologies
beyond those based on monoclonal antibodies and small
organic molecules are likely to follow.
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